Vartika Srivastava, Sougata Sarkar, Jyotirmoyee Jena, Manjushree Mohanty


Background: The principal aim of drug utilisation studies (DUS) is to facilitate the rational use of drug  in a population.DUS is an essential part of pharmacoepidemiology and pharmacoeconomic as it describes the extent,nature and determinants of drug exposure. Diabetes at present appears as a common non communicable disease. It leads to high morbidity and mortality due to the disease itself and its diverse complications like coronary artery disease, hypertension, renal complication, retinal damage, neurological disorders, incidence of stroke at different sites, generalised infections etc. With such multifactorial background of high prevalence , progressive nature of the disease, availability of multiple therapeutic regimens prescribed on trial and error basis, the treatment is individualised and neither complete nor satisfactory. Objectives: This study was undertaken to analyse the current prescribing pattern in obese patients of type 2 diabetes mellitus with regard to drug/drugs precription  ,dose, duration of treatment  and frequency of change of drugs. Methods: This is a  prospective, parallel group, comparitive observational study. The enrolled obese patients were divided as a)New diabetic b) Old diabetic(<3 years duration). Each category was further divided into four subgroups according to the treatment recieved a)Monotherapy-only Metformin b)Combination therapy- Metformin+another antidiabetic groups,preferably sulfonylureas, alphaglucosidase inhibitors or DPP 4 inhibitors c)Triple therapy( Metformin+SU+Voglibose or Gliptins or Glitazones) d)Insulin with other oral hypoglycemic drugs. Results: In the study of prescribing pattern, it was observed that most prescriptions in this tertiary care hospital were found to be in compliance with the ADA guidelines. Metformin monotherapy was prescribed  as initial treatment. Sulphonylureas/ Gliptins / Alpha glucosidase inhibitors/  thiazolidinediones  were  used as second line therapy mostly anyone,  in addition to metformin or as monotherapy according to patient requirement, tolerability and cost.Conclusions: The antidiabetic medications prescribed in this hospital,were found to be in compliance with  ADA guidelines with metformin being the first line of treatment followed by sulfonylureas and alphaglucosidase inhibitors


Diabetes, Obese, Pre-obese, FBS, PPBS, HbA1C

Full Text:



Bakssas I.Lunde PKM.National drug utilisation policies :the need for drug utilisation studies.Trends pharmacol Soc 1986;7:331

Abdi SA, Churi S, Kumar YS. Study of drug utilization pattern of antihyperglycemic agents in a South Indian tertiary care teaching hospital. Indian J Pharmacol 2012;44:210-4

Mino-León D, Figueras A, Amato D.Treatment of type 2 diabetes in primary health care: a drug utilization study. Ann Pharmacother. 2005 Mar;39(3):441-5.

Comfort O.Olurishe 2012:Drug Utilisation review of anti diabetic medications and therapeutic outcome in type 2 diabeters in tertiary hospital in Nigeria. West African Journal of Pharmacy(2012)23(2)58-64

WHO Expert committee. The use of essential drugs. World Health Organ Tech Rep Ser. 2000; 895: 1-61

Database: Department of Health and Family Welfare, Government of Odisha

Generic Pharmaceutical Association (GPhA). Economic Analysis of Generic Pharmaceuticals :1999-2008 USD 734 billion in healthcare savings. http://www.gphaonline.org accessed 9.25 a.m. 25th August, 2009

Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29(8):1963–72.

The Joint Formulary Committee. British National Formulary (BNF) Volume 62 September Issue. London: BMJ group and Pharmaceutical Press; 2011.

Charbonnel B, Shernthaner G, Brunetti P: Long-term efficacy and tolerability of add-on piogçitazone therapy to faliling monotherapy compared with addition of glicazide or metformin in patients with type 2 diabetes. Diabetologia. 2005, 48: 1093-1104. 10.1007/s00125-005-1751-1.

Hanefeld M, Brunetti P, Schhernthaner GH: One year glycemic control with sulphonylurea plus pioglitazone versus sulphonylurea plus metformin in patients with type 2 diabetes. Diabetes Care. 2004, 27: 141-147. 10.2337/diacare.27.1.141.

González-Ortiza M, Guerrero-Romero J, Violante-Ortiz R: Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus. J Diabetes Complications. 2009, 23: 376-379. 10.1016/j.jdiacomp.2008.09.002

Johnson JA, Majumdar SR, Simpson SH: Decreased mortality associated with the use of metformin compared with sulfonylurea Monotherapy in type 2 diabetes. Diabetes Care. 2002, 25: 2244-2248. 10.2337/diacare.25.12.2244.

Evans JM, Ogston SA, Emslie-Smith A, Morris AD: Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia. 2006, 49: 930-936. 10.1007/s00125-006-0176-9.

Markus R. Alpha glucosidase inhibitors. In Derek L., Simeon C., Olefsky J.M., Ed Diabetes Mellitus – A fundamental andclinical text, 3rd Edn. Lippincott Williams and Wilkins publisher: 1151-56, (2004)

Braun D, Schonherr U, Mitzkat H-J: Efficacy of acarbose monotherapy in patients with type 2 diabetes: a double-blind study conducted in general practice. Endocrin Metab 3:275–280, 1996

Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract. 2006;60(11):1454-1470

White JR. Dipeptidyl peptidase-IV inhibitors: pharmacological profile and clinical use. Clin Diabet. 2008;26(2):53-57.

Neumiller JJ. Differential chemistry (structure), mechanism of action and pharmacology of GLP-receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc. 2009;49 Suppl:S16-S29.

Pathak R, Bridgeman MB. Dipeptidyl peptidase-4 (DPP-4) inhibitors in the management of diabetes. PT. 2010;35(9):509-513.

Bailey CJ, Bagdonas A, Rubes J: Rosiglitazone-metformin fixed-dose combination compared with uptritrated metformin alone in type diabetes mellitus:a 24 week, multicenter, randomized, double-blind, parallel-group study. Clin Ther. 2005, 27: 1548-1561. 10.1016/j.clinthera.2005.10.012.

Retnakaran R, Qi Y, Harris SB, Hanley AJ, Zinman B: Changes over time in glycemic control, insulin sensitivity, and beta-cell function in response to low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance. Diabetes Care. 2011, 34 (7): 1601-1604. 10.2337/dc11-0046.

Scheen AJ: ADOPT study: which first-line glucose-lowering oral medication in type 2 diabetes?. Rev Med Liege. 2007, 62 (1): 48-52.

Ferwana M1, Firwana B, Hasan R, Al-Mallah MH, Kim S, Montori VM, Murad MH; Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies; Diabet Med. 2013 Sep;30(9):1026-32. doi: 10.1111/dme.12144.

Giugliano D, Quatraro A, Consoli G: Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol. 1993, 44: 107-112. 10.1007/BF00315466.

Lund SS, Tarnow L, Frandsen M: Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial. BJ. 2009, 339: b4324-10.1136/bmj.b4324.

Vella S, Buetow L, Royle P: The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia. 2010, 53 (5): 809-820. 10.1007/s00125-009-1636-9.

Abdelghaffar S, Attia AM: Metformin added to insulin therapy for type 1 diabetes mellitus in adolescents. Cochrane Database Syst Rev. 2009, CD006691-Issue 1


  • There are currently no refbacks.